The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032

The Business Research Company’s nephrology drugs market report forecasts the nephrology drugs market size to grow to $5.66 Billion by 2027, with a CAGR (compound annual growth rate) of more than 20%.

Learn More On The Nephrology Drugs Market Report 2023 – https://www.thebusinessresearchcompany.com/report/nephrology-drugs-global-market-report

Nephrology Drugs Market Size Forecast
The global nephrology drugs market is expected to grow from $15.37 billion in 2022 to $16.18 billion in 2023 at a compound annual growth rate (CAGR) of 5.24%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global nephrology drugs market size is expected to reach $5.66 billion in 2027 at a CAGR of 20.16%.

North America held the largest nephrology drugs market share.

Key Nephrology Drugs Market Driver ­– Rise In The Prevalence Of Chronic Kidney Disease
According to reports shared by the Centres for Disease Control and Prevention (CDC), a US-based health protection agency, it was estimated in July 2022 that more than 37 million people in the US were diagnosed with chronic kidney disease, which is more common in people aged 65 and older (38%). Furthermore, according to the Kidney Foundation of Canada, a non-profit organisation established in Canada, 4 million Canadians suffer from kidney illnesses. Diabetic patients account for 35% of all renal failure cases. These figures are projected to climb in the coming years. As a result, the increased prevalence of chronic kidney disease is propelling the nephrology drug market forward.

Request for A Sample Of The Global Nephrology Drugs Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10076&type=smp

Key Nephrology Drugs Market Trend – Product Innovation
To maintain their market position, major players in the nephrology medicine market are developing new goods and drugs. For example, Zydus Lifesciences Limited., an Indian pharmaceutical company, launched OxemiaTM (desidustat) for chronic kidney disease (CKD) in March 2022. It is an oral, small-molecule hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitor that provides a straightforward therapy alternative for anaemia. And it has been certified by India’s Drug Controller General. clinical trials in Phase III In chronic renal disease patients, it displayed good safety profiles, hepcidin downregulation, improved iron mobilisation, and a reduction in LDL-C. Furthermore, by offering therapy at a fair cost and improving patients’ quality of life, the illness burden will be reduced.

Nephrology Drugs Market Segment
1) By Drugs: Antihypertensive Agents, Erythropoiesis-Stimulating Agents, Diuretics, ACE Inhibitors, Antidiabetic Agents, and Other Drugs
2) By Route Of Administration: Oral, Parenteral, or Other Route Of Administration
3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

Nephrology Drugs Market Major Players and Strategies
Major players in the nephrology drugs market are AstraZeneca PLC, AbbVie Inc., Akebia Therapeutics Inc., Amgen Inc., F. Hoffmann-La Roche AG, FibroGen Inc., Johnson And Johnson Inc., Pfizer Inc., GSK PLC, Teva Pharmaceutical Industries Limited, Boehringer Ingelheim International GmbH, Reata Pharmaceuticals Inc., Ardelyx Inc., Novo Nordisk A/S and Novartis AG.

CSL Behring AG, a Swiss pharmaceutical corporation, paid $11.7 billion for Vifor Pharma AG in December 2021. CSL Behring AG improves, diversifies, and enriches its product portfolio with this acquisition by adding a high-quality, complementary range of nephrology products that address iron deficiency, among other ailments. Vifor Pharma AG is a global pharmaceutical firm established in Switzerland that develops dialysis and nephrology products and services.

The Nephrology Drugs Global Market Report 2023 covers regional data on nephrology drugs market size, nephrology drugs market trends and drivers, opportunities, strategies, and nephrology drugs market competitor analysis. The countries covered in the nephrology drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA, and the major seven regions are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

Nephrology drugs, often known as renal pharmaceuticals, are medications used to treat kidney disease. These medications are frequently linked to high blood pressure and hypertension. It is used to try to improve kidney function and slow down the disease, stopping it from causing more harm to the body.

View More Reports Related To The Nephrology Drugs Market –
Nephrology And Urology Devices Global Market Report 2023
Drugs For Immunotherapy Global Market Report 2023
Drugs Of Abuse (DOA) Testing Global Market Report 2023

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on: